Core Viewpoint - The "1+6" reform of the Sci-Tech Innovation Board is accelerating, with the first IPO registration under the fifth set of standards being approved for Wuhan Heyuan Biotechnology Co., Ltd. on July 18, 2025, alongside Shenzhen Beixin Life Technology Co., Ltd. passing the listing committee meeting on the same day [1][2]. Group 1: Company Developments - Wuhan Heyuan Biotechnology is a biopharmaceutical company that reported revenues of 13.40 million, 24.26 million, and 25.22 million yuan for 2022, 2023, and 2024 respectively, with net losses of 144 million, 187 million, and 151 million yuan during the same period [4]. - The company has no approved drugs yet, and the approval of its recombinant human albumin injection (trade name: Aofumin) marks the beginning of its drug commercialization process [4]. - Shenzhen Beixin Life Technology focuses on innovative medical devices for cardiovascular disease diagnosis and treatment, with 17 approved and in-development products as of the prospectus date [5]. Group 2: Market Context - The China Securities Regulatory Commission (CSRC) announced the establishment of a growth tier for the Sci-Tech Innovation Board and the resumption of the fifth set of standards for unprofitable companies on June 18, 2025 [1]. - The Shanghai Stock Exchange implemented new rules for the Sci-Tech Innovation Board on July 13, 2025, allowing newly listed unprofitable companies to enter the growth tier immediately upon listing [1]. - The listing guidance for Hangzhou Yushu Technology Co., Ltd. has commenced, with the company undergoing a name change and restructuring to facilitate its IPO process [6][7].
“1+6”改革加速落地：禾元生物IPO注册生效、北芯生命上市过会 宇树科技开启上市辅导
Zhong Guo Jing Ying Bao·2025-07-19 02:52